Application of 3D visualization and 3D printing technology in interventional therapy of structural heart disease / 中华胸心血管外科杂志

3D visualization technology is the process of transforming two-dimensional image data into three-dimensional model with the help of computer software. 3D printing technology is the process of building organ solid model through 3D printing mechanism on the basis of 3D visualization. With the development of interventional technology for structural heart disease, 3D visualization and 3D printing technology have played a positive role in the understanding of cardiac anatomy and the formulation of personalized surgical plans. This paper will discuss the construction of 3D visualization model, review and analyze the application of 3D printing technology in interventional therapy of structural heart disease in recent years, discuss the future development in this field, and briefly analyze its existing problems.

Efficacy and safety of transapical transcatheter aortic valve replacement in the treatment of aortic regurgitation in patients with large aortic annulus / 中国胸心血管外科临床杂志

@#Objective    To investigate the feasibility and safety of transcatheter aortic valve replacement (TAVR) through apical approach for aortic regurgitation of large annulus. Methods    From November 2019 to May 2020, 10 male patients aged 64.50±4.20 years with aortic valve insufficiency (AI) underwent TAVR in the Department of Cardiovascular Surgery, Xijing Hospital. The surgical instruments were 29# J-valveTM modified and the patients underwent TAVR under angiography. The preoperative and postoperative cardiac function, valve regurgitation, complications and left ventricular remodeling were summarized by ultrasound and CT before and after TAVR. Results    A total of 10 valves were implanted in 10 patients. Among them, 1 patient was transferred to the aortic arch during the operation and was transferred to surgical aortic valve replacement; the other 9 patients were successfully implanted with J-valve, with 6 patients of cardiac function (NYHA) class Ⅱ, 4 patients of grade Ⅲ. And there was a significant difference between preoperation and postoperation in left ventricular ejection fraction (44.70%±8.78% vs. 39.80%±8.48%, P<0.05) or aortic regurgitation (1.75±0.72 mL vs. 16.51±8.71 mL, P<0.05). After 3 months, the patients' cardiac function was good. Conclusion    TAVR is safe and effective in the treatment of severe valvular disease with AI using J-valve.